Gland Pharma Limited has strengthened its senior management team with the appointment of Mr. Prasadha Rao Lysetti as Senior Vice-President (Head - Operations), effective April 06, 2026. The pharmaceutical company announced this key leadership addition in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Appointment Details

The appointment represents a strategic addition to Gland Pharma's operations leadership, with Mr. Lysetti assuming the role of Senior Management Personnel within the organization.

Professional Background and Expertise

Mr. Prasadha Rao Lysetti brings extensive pharmaceutical industry experience to his new role at Gland Pharma. His professional profile demonstrates significant expertise in pharmaceutical manufacturing and operations management.

Experience and Specialization

• Industry Experience: 25+ years of progressive expertise
• Core Competencies: Managing complex formulations and large-scale pharmaceutical manufacturing
• Operational Focus: Quality-centric operations and operational efficiency enhancement
• Leadership Areas: Lean and operational excellence initiatives
• Global Exposure: Experience across diverse cultures and global locations

Career History

Prior to joining Gland Pharma, Mr. Lysetti held positions at several prominent pharmaceutical organizations:

• Cronus Pharma India Private Limited (Rising Pharmaceuticals Group)
• Vitema Pharmaceuticals
• Eugia Pharma Specialities Limited
• Dr. Reddy's Laboratories Limited
• Glenmark Generics Ltd
• Pharma Care FZE LLC

Educational Qualifications and Certifications

Mr. Lysetti's educational background reflects his commitment to continuous learning and professional development:

Strategic Significance

The appointment of Mr. Lysetti as Senior Vice-President (Head - Operations) aligns with Gland Pharma's focus on operational excellence and manufacturing efficiency. His extensive experience in pharmaceutical operations and proven track record in quality management and operational improvements position him to contribute significantly to the company's operational objectives.

The company has fulfilled all disclosure requirements under SEBI regulations, providing comprehensive details about the appointment in accordance with regulatory guidelines.

Gland Pharma Limited has announced its updated schedule for analyst and institutional investor meetings, with a confirmed meeting scheduled for March 23, 2026. The pharmaceutical company submitted this intimation to both BSE Limited and National Stock Exchange of India Limited on March 18, 2026, in compliance with regulatory requirements.

Updated Meeting Schedule

The company has organized a focused engagement with the investment community, moving from the previously announced March 18-20 schedule to a specific confirmed meeting. The updated schedule provides clarity on the investor interaction program with confirmed participants.

Regulatory Compliance Framework

The intimation was filed pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to inform stock exchanges about material events and investor interactions.

Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the official communication digitally on March 18, 2026. The document was addressed to both major Indian stock exchanges where the company's shares are listed.

Meeting Format and Flexibility

Gland Pharma has maintained that the meeting schedule remains subject to change. The company specifically noted that modifications may occur due to exigencies on the part of the investor, analyst, or the company itself. This flexibility clause ensures that all parties can accommodate any unforeseen circumstances that might affect the planned interactions.

The one-on-one meeting format with Ventura Securities allows for detailed discussions about the company's business performance, strategic initiatives, and market outlook. Such meetings are standard practice for listed companies to maintain regular communication with their investor base and analyst community.